Hepatocellular carcinoma (HCC)

Request an Appointment

Stages

Your healthcare team uses the results from diagnostic tests and procedures to give your cancer a stage. The stage tells your healthcare team about how severe your cancer is and how well your liver is working.

There are different systems used for hepatocellular carcinoma staging. Some use numbers and some use letters. One system that is commonly used is called the Barcelona Clinic Liver Cancer Staging System. This system has five stages. It uses the number 0 for the earliest stage of cancer and letters A through D for the other stages.

Using this staging system, the stages of hepatocellular carcinoma are:

  • Stage 0, also called very early stage. Stage 0 hepatocellular carcinoma means there is one growth of cancer cells, called a tumor, in the liver that is smaller than 2 centimeters (a little more than 3/4 inch). The tumor has not spread to blood vessels or outside the liver.
  • Stage A, also called early stage. Stage A hepatocellular carcinoma means there is one tumor in the liver that is larger than 2 centimeters (a little more than 3/4 inch). Or it may mean that there are up to three tumors that are each smaller than 3 centimeters (a little more than 1 inch). The tumors have not spread to blood vessels or outside the liver.
  • Stage B, also called intermediate stage. Stage B hepatocellular carcinoma means there are more tumors than stage A and they may be larger. The tumors may affect different parts of the liver. The tumors have not spread to blood vessels or outside the liver.
  • Stage C, also called advanced stage. Stage C hepatocellular carcinoma means the tumors have grown to involve the blood vessels or the cancer cells have spread beyond the liver. When cancer spreads away from where it started, it's called metastatic cancer.
  • Stage D, also called end stage. Stage D hepatocellular carcinoma means the liver is not healthy enough to have treatment. This is because cirrhosis is so severe. The healthcare team might focus on comfort care, rather than trying to cure the cancer.
Request an appointment
Diagnosis & treatmentSurvival rates
Sept. 11, 2025

Living with hepatocellular carcinoma (HCC)?

Connect with others like you for support and answers to your questions in the Transplants support group on Mayo Clinic Connect, a patient community.

Transplants Discussions

lmctif
Liver transplant - Let's support each other

1688 Replies Fri, Aug 08, 2025

Curses
MELD score less than 15?

12 Replies Tue, Jul 15, 2025

See more discussions
  1. Elsevier Point of Care. Clinical Overview: Hepatocellular carcinoma. https://www.clinicalkey.com. Accessed Nov. 18, 2024.
  2. Hepatocellular carcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514. Accessed July 25, 2025.
  3. Primary liver cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq. Accessed Nov. 18, 2024.
  4. Liver (hepatocellular) cancer prevention (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/liver/hp/bile-duct-treatment-pdq. Accessed Nov. 18, 2024.
  5. Schwartz JM, et al. Clinical features and diagnosis of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed July 30, 2025.
  6. Abdalla EK, et al. Overview of treatment approaches for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  7. Stuart KE. Systemic treatment for advanced hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  8. Schwartz JM, et al. Epidemiology and risk factors for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  9. Curley SA, et al. Surgical resection of hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Nov. 18, 2024.
  10. Tsoulfas G, et al. Liver transplantation for hepatocellular carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 5, 2025.
  11. Palliative care. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed Nov. 18, 2024.
  12. Hepatitis C prevention and control. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-c/prevention/index.html. Accessed Nov. 18, 2024.
  13. 2020-2025 Dietary Guidelines for Americans. U.S. Department of Health and Human Services and U.S. Department of Agriculture. https://www.dietaryguidelines.gov. Accessed Nov. 18, 2024.
  14. TACE. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/chemoembol. Accessed Nov. 18, 2024.
  15. Radioembolization (Y90). RadiologyInfo.org. https://www.radiologyinfo.org/en/info/radioembol. Accessed Nov. 18, 2024.
  16. Thermal ablation for tumor treatment. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/thermal-ablation-therapy. Accessed Nov. 18, 2024.
  17. Liver cancer. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/liver-cancer/about/index.html. Accessed Nov. 18, 2024.
  18. Hepatitis B vaccine. U.S. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis-b/vaccination/index.html. Accessed Feb. 7, 2025.
  19. Feldman M, et al., eds. Hepatic tumors and cysts. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 11th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed July 25, 2025.
  20. DeVita VT Jr, et al., eds. Cancer of the liver. In: DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology. 12th ed. ProQuest Ebook Central. Wolters Kluwer; 2023. Accessed Feb. 11, 2025.
  21. Suriawinata A. Pathology of malignant liver tumors. https://www.uptodate.com/contents/search. Accessed July 25, 2025.
  22. Kalman RS, et al. Epidemiology, clinical manifestations, diagnosis and treatment of fibrolamellar carcinoma. https://www.uptodate.com/contents/search. Accessed Aug. 6, 2025.
  23. Ferri FF. Jaundice in the adult patient. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  24. McPherson RA, et al., eds. Evaluation of liver function. In: Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2022. https://www.clinicalkey.com. Accessed Aug. 1, 2025.
  25. Reig M, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022; doi:10.1016/j.jhep.2021.11.018.
  26. Cancer stat facts: Liver and intrahepatic bile duct cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/livibd.html. Accessed Aug. 5, 2025.
  27. Tecentriq (prescribing information). Genentech; 2024. https://www.tecentriq.com. Accessed Aug. 5, 2025.
  28. Lenvima (prescribing information). Eisai; 2025. https://www.lenvima.com. Accessed Aug. 5, 2025.
  29. Health Education & Content Services. Liver cancer: Hepatocellular carcinoma. Mayo Clinic; 2023.
  30. Nimmagadda R. Allscripts EPSi. Mayo Clinic. Feb. 26, 2025.
  31. Liver SPOREs. National Cancer Institute. https://dctd.cancer.gov/research/spores/focus-area/liver. Accessed Aug. 6, 2025.
  32. Santol J, et al. An APRI+ALBI-based multivariable model as preoperative predictor for posthepatectomy liver failure. Annals of Surgery. 2023; doi:10.1097/SLA.0000000000006127.
  33. Starlinger P, et al. Combined APRI/ALBI score to predict mortality after hepatic resection. BJS Open. 2021; doi:10.1093/bjsopen/zraa043.
  34. Kern AE, et al. MicroRNA based prediction of posthepatectomy liver failure and mortality outperforms established markers of preoperative risk assessment. Annals of Surgical Oncology. 2025; doi:10.1245/s10434-025-17528-x.
  35. Dong Y, et al. Preoperative von Willebrand factor is an independent predictive biomarker for posthepatectomy liver failure — A multivariable model with APRI+ALBI. Liver Transplantation. 2025; doi:10.1097/LVT.0000000000000676.

Related

Associated Procedures

Products & Services

Hepatocellular carcinoma (HCC)